Hydralazine as Demethylating Agent in Breast Cancer
NCT00575978
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
IRB request
Conditions
Breast Cancer
Interventions
DRUG:
Hydralazine
Sponsor
University of Arkansas